Amneal Pharmaceuticals, Inc.
AMRX
주식 순위
#2968
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is... Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
주가
$19.39
마지막 동기화: 2026-10-19
시가총액
$6.19B
변동 (1일)
1.09%
변동 (1년)
89.36%
국가
US
거래 Amneal Pharmaceuticals, Inc. (AMRX)
카테고리
Healthcare
Amneal Pharmaceuticals, Inc. (AMRX)의 P/E 비율
October 2026 기준 P/E 비율 TTM: 37.99
Amneal Pharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 37.99입니다. 2023년 말 기준 P/E 비율은 -12.65였습니다.
Amneal Pharmaceuticals, Inc.의 P/E 비율 기록 (2014 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 37.99 | -281.42% |
| 2024 | -20.94 | 65.56% |
| 2023 | -12.65 | 447.22% |
| 2022 | -2.31 | -103.44% |
| 2021 | 67.14 | 796.23% |
| 2020 | 7.49 | -810.26% |
| 2019 | -1.05 | -89.60% |
| 2018 | -10.14 | -188.93% |
| 2017 | 11.41 | -5.54% |
| 2016 | 12.08 | -74.68% |
| 2015 | 47.69 | 40.93% |
| 2014 | 33.84 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -7.98% |
IN
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.